Note to readers: This article is to notify researchers to the possibilities of Metadichol as a mediator of the AHR-Nrf2 pathway for inflammatory response. Metadichol’s action on nuclear receptors is hugely significant. The importance of Metadichol’s effect is in regulating inflammatory response to outside agents. Outside agents may include drugs, manmade toxins, or even response to light (think sunburn and/or retinal protection). In this paper, it is shown how Metadichol may be significant in treating chemo resistant cancer.

Metadichol ®. A Novel Inverse Agonist of Aryl Hydrocarbon Receptor (AHR) and NRF2 Inhibitor
Journal of Cancer Science and Therapy 

Raghavan, P R
Nanorx Inc., Chappaqua, New York, USA,  

Abstract
Metadichol ® a novel nano-emulsion of lipid alcohols is an Inverse agonist of Vitamin D Receptor (VDR). In this communication, we show that Metadichol is an inverse agonist of the nuclear receptor AHR (Aryl Hydrocarbon receptor) and an inhibitor of NRF2 (Nuclear factor (erythroid-derived 2)-like 2)) and is a transcription factor that is ubiquitously expressed at low levels in all human organs and regulates a primary cellular defense mechanism, tight regulation to maintain cellular homeostasis. AHR is highly expressed in a broad panel of tumors, AHR is induced by 2,3,7,8-tetrachloride-benzo-p-dioxin (TCDD) Metadichol® as a inverse agonist against AHR could be potentially useful in the treatment of such diseases. Strong in vivo evidence suggests that TCDD can stimulate cross-talk between AHR and Nrf2. The constitutive up regulation of Nrf2 signaling appears to drive the cellular proliferation and resistance to chemotherapy in various cancers. Therefore, pharmacological inhibition of Nrf2 by Metadichol ® holds promise as a therapeutic strategy in chemo resistant forms of cancer. 

Here is a link to the PDF: metadichol-AHR-Paper